Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 4Phase EARLY_PHASE1 2Phase 1/2 2Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neoplasm Metastasis 30Prostatic Neoplasms 18Lung Neoplasms 17Breast Neoplasms 17Glioblastoma 16Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 14Pancreatic Neoplasms 13Multiple Myeloma 12Glioma 12Brain Neoplasms 11Carcinoma, Renal Cell 10Squamous Cell Carcinoma of Head and Neck 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Follicular 9Astrocytoma 9Neoplasms 8Melanoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Lymphoma, Non-Hodgkin 7Cholangiocarcinoma 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 6Gliosarcoma 6Central Nervous System Neoplasms 6Carcinoma 6

Interventions

Cyclophosphamide 32Filgrastim 18Irinotecan 15Topotecan 14Temozolomide 13Vincristine 12Peripheral Blood Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 12Etoposide 12Melphalan 11fludarabine 10Carboplatin 9dinutuximab 8Isotretinoin 8Interleukin-2 8Busulfan 8humanized 3F8 anti-GD2 monoclonal antibody 7aldesleukin 7Doxorubicin 73-Iodobenzylguanidine 7sargramostim 6fludarabine phosphate 6Vorinostat 6Zoledronic Acid 5Stem Cell Transplantation 5Cisplatin 5etoposide phosphate 4Ipilimumab 4Drug Therapy 4ribociclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroblastoma × Magnetic Resonance Spectroscopy × Clear all
NCT04751383 2026-01-21

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled 12 charts
CNSSarcoma

Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡